Shared by Ken Dropiewski on October 25, 2022 Patent builds on previously granted U.S. patent as well as strengthens and diversifies the IP portfolio and further protects future revenues Southlake, Texas, Oct. 25,…
Patent builds on previously granted U.S. patent as well as strengthens and diversifies the IP portfolio and further protects future revenues Southlake, Texas, Oct. 25, 2022 — Heart Test Laboratories, Inc. d/b/a…
CEO Andrew Simpson discusses how we’re one of the only companies leading the use of an AI-enabled EKG medical device to make it a far more valuable screening tool. https://twitter.com/i/status/1584532158261100545
Southlake, Texas, Oct. 20, 2022 — Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on saving lives by making an ECG (also known as…
Chairman & CEO, Andrew Simpson, Describes AI-based Technology EKG Test and Next Steps for Commercialization https://youtu.be/0G8lDMfZnpA
Heart Test Laboratories' Chairman & CEO, Andrew Simpson, Describes AI-based Technology EKG Test and Next Steps for Commercialization https://youtu.be/0G8lDMfZnpA
